IL24 and neoplasm: In 2005, a Phase‐I clinical trial involving intra‐tumoral administration of INGN 241, an adenovirus construct expressing the IL‐24 transgene, was conducted in 28 patients with resectable solid tumors representing 15 different tumor types, who had received prior treatment with surgery in combination with radiation or chemotherapy.